Pharsight

Biofrontera patents expiration

1. Ameluz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11540981 BIOFRONTERA Nanoemulsion formulation with improved stability and cell penetration
Feb, 2028

(3 years from now)

US11235169 BIOFRONTERA Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device
Oct, 2040

(16 years from now)

Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient

Market Authorisation Date: 10 May, 2016

Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminat...

Dosage: GEL;TOPICAL

More Information on Dosage

AMELUZ family patents

Family Patents